HOSPITAL UNIVERSITARIO RUBER
Department
University of North Carolina at Chapel Hill
Chapel Hill, Estados UnidosPublications in collaboration with researchers from University of North Carolina at Chapel Hill (32)
2024
-
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)
Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3
2023
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659
-
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
European Journal of Cancer, Vol. 178, pp. 23-33
-
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
JAMA Oncology, Vol. 9, Núm. 4, pp. 490-499
2022
-
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
eBioMedicine, Vol. 75
-
Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
European Journal of Cancer, Vol. 171, pp. 25-42
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
npj Breast Cancer, Vol. 8, Núm. 1
-
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
npj Breast Cancer, Vol. 8, Núm. 1
-
Targeting brain metastases in breast cancer
Cancer Treatment Reviews, Vol. 103
2021
-
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
Future Oncology, Vol. 17, Núm. 30, pp. 3911-3924
-
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156
-
Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3116-3125
-
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
EBioMedicine, Vol. 69
-
Sacituzumab govitecan in metastatic triple-negative breast cancer
New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541
-
The Global Landscape of Treatment Standards for Breast Cancer
Journal of the National Cancer Institute, Vol. 113, Núm. 9, pp. 1143-1155
2020
-
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Journal of the National Cancer Institute, Vol. 112, Núm. 1, pp. 46-54